Endofotonics is a medtech organisation dedicated to using its proprietary Raman spectroscopy platform technology to improve early cancer detection and hence reduce cancer burden in patients. To find out more, visit us at www.endofotonics.com or email your enquiries to contact@endofotonics.com Follow and like us on facebook.com/endofotonics _ Founded in 2013, the company is headquartered in Singapore and has a subsidiary in Shanghai, China. Endofotonics developed the SPECTRA IMDx™ system, the world's first real-time in-vivo Raman spectroscopy platform, that improves early gastric cancer detection rate. Endofotonics is currently ran by a lean team of highly skilled and specialized engineers and PhD executives, with knowledge ranging from optics to biomedical, and skills from academic research to industrial product development. Overseeing Endofotonics as a business, the company is supported by board of directors and engineering scientific board that comprises of founders and thought leaders in their own field. Endofotonics raised S$12 million in Series B funding earlier this year. This funding will be used to support the commercialisation of the SPECTRA IMDx in Asia Pacific and beyond.